The coronavirus pandemic has had a major financial impact on the world’s capital markets. However, some biopharma companies have seen this as an opportunity for unprecedented growth in value.
Financial data from GlobalData’s Pharma Intelligence Center Companies Database reveals that small cap ($0.3–2.0B) public companies working on the development of a Covid-19 drug are witnessing growth in market cap among the plunge of other industries.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
